Status note Lead program. Investigator-sponsored Phase 1 completed primary enrollment; RP2D determined; expansion cohort at RP2D enrolling (target up to 15 additional patients, minimum 25 total).
INB-200
Phase 1 · ActiveModality: cell therapy (drug-resistant immunotherapy, DeltEx DRI gamma-delta T cells engineered with MGMT-expressing lentivector)
Indications
Newly diagnosed glioblastoma (GBM)(Phase 1)
Status note Investigator-sponsored Phase 1 (NCT04165941) dosing completed; patients followed for PFS/OS. Peer-reviewed Phase 1 data published in JCO July 2026.
Status note Phase 2 enrollment suspended September 2024 following pipeline review to conserve capital; treatment of enrolled patients completed, IND remains open (10-K). DeltEx DRI gamma-delta T cells in newly diagnosed GBM.
INB-619
Preclinical · ActiveModality: T cell engager (gamma-delta TCE, INB-600 platform)
Status note Proprietary internally developed INB-600 TCE platform candidate; deep B-cell depletion via selective gamma-delta T cell activation/expansion shown (ACR Convergence 2025).
INB-300
Preclinical · ActiveModality: cell therapy (targeted non-signaling gamma-delta T cell based CAR construct, nsCAR)
Target CD33/CD123
Status note Preclinical program suspended in development due to pipeline prioritization and market conditions; not formally discontinued.
INB-500
Preclinical · ActiveModality: cell therapy (gamma-delta T cells from iPSCs)
Status note Preclinical iPSC gamma-delta T cell program suspended in development due to pipeline prioritization and market conditions; not formally discontinued.
Per-asset detail extracted from the 10-Q filed 2026-08-06. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Pipeline
Lead drug
Autologous genetically modified gamma-delta T cells
Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 1 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.